ClinicalTrials.gg
CompletedNCT00695955Updated Apr 19, 2011Results posted

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

A Phase 3 interventional study of Azilsartan medoxomil with or without add-on chlorthalidone and Azilsartan medoxomil with or without add-on hydrochlorothiazide in Hypertension, sponsored by Takeda. Completed at 41 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
669
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.

Enrollment
7th of 11
669 · median 837
Started
2007
with 2 others
Phase 3
10 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
11 of 11
Takeda

Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 10 in phase 3, and was the 1st registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing azilsartan medoxomil in Essential Hypertension as a file.
02

Study summary

This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.

Read the detailed description

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.

Takeda Global Research and Development is developing TAK-491 (azilsartan medoxomil) for the treatment of essential hypertension. This study is being conducted to demonstrate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.

Study participation is anticipated to be approximately 1 year and 1.5 months, and participants will be required to return to the clinic for 10 study visits.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Essential Hypertension
  • Cardiovascular Disease
  • High Blood Pressure
  • Drug Therapy
04

In context

Essential Hypertension Reclassified

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

This study's enrollment of 669 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diastolic blood pressure greater than or equal to 95 mm Hg and less than or equal to 119 mm Hg. For diabetic subjects and subjects with chronic kidney disease, diastolic blood pressure must be greater than or equal to 85 mm Hg and less than or equal to109 mm Hg).
  2. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating.
  3. Clinical laboratory evaluations within the reference range for or deemed not by the investigator.

Exclusion criteria

Exclusion Criteria

  1. Systolic blood pressure greater than 185 mm Hg.
  2. Expected to take angiotensin II receptor blockers other than the study drug.
  3. Taking more than 2 antihypertensive agents.
  4. Hypersensitive to angiotensin II receptor blockers, thiazide-type diuretics or sulfonamide-derived compounds.
  5. Recent history of major cardiovascular event.
  6. History of moderate to severe heart failure or hypertensive encephalopathy.
  7. cardiac conduction defects.
  8. Secondary hypertension of any etiology.
  9. Known or suspected unilateral or bilateral renal artery stenosis.
  10. Severe renal dysfunction or disease.
  11. History of drug abuse or a history of alcohol abuse within the past 2 years.
  12. Previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug..
  13. Uncontrolled diabetes mellitus.
  14. level of greater than 2.5 times the , active liver disease, or jaundice.
  15. Serum potassium level of greater than the upper limit of normal.
  16. Currently is participating in another study or has participated in an investigational study within 30 days prior to enrollment.
  17. Any other serious disease or condition.
  18. Randomized in a previous azilsartan medoxomil study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
669 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil

    Drug: Azilsartan medoxomil with or without add-on chlorthalidone · Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide

Interventions

  • DrugAzilsartan medoxomil with or without add-on chlorthalidone

    Drug page: Azilsartan medoxomil

    Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.

    Also known as: TAK-491, Edarbi

  • DrugAzilsartan medoxomil with or without add-on hydrochlorothiazide

    Drug page: Azilsartan medoxomil

    Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.

    Also known as: TAK-491, Edarbi

07

What researchers measure

Primary outcomes

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.

    Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.

    Time frame: 56 weeks.

  2. Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.

    Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.

    Time frame: 56 weeks.

Secondary outcomes

  1. Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 1.

    The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.

    Time frame: 52 weeks

  2. Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 2

    The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.

    Time frame: 52 weeks

  3. Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 1.

    The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.

    Time frame: 52 weeks.

  4. Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 2.

    The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.

    Time frame: 52 weeks.

08

Results

Posted Apr 19, 2011

Participant flow

Participants enrolled at 39 investigative sites in Chile, Mexico and the United States from 22 June 2007 to 30 April 2010.

Cohort 1
Participant flow — Cohort 1
MilestoneAzilsartan Medoxomil
Started362
Completed260
Not completed102
Withdrew: Adverse event26
Withdrew: Protocol violation2
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject25
Withdrew: Lack of efficacy3
Withdrew: Other16
Cohort 2
Participant flow — Cohort 2
MilestoneAzilsartan Medoxomil
Started307
Completed203
Not completed104
Withdrew: Adverse event24
Withdrew: Protocol violation5
Withdrew: Lost to follow-up38
Withdrew: Withdrawal by subject28
Withdrew: Lack of efficacy4
Withdrew: Other5

Outcome measures

PrimaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.

Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.

Time frame:
56 weeks.
Reported as:
Number · participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.
participantsCohort 1
Number of Participants267
Percentage of Participants73.8
PrimaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.

Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.

Time frame:
56 weeks.
Reported as:
Number · participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.
participantsCohort 2
Number of Participants241
Percentage of Participants78.5
SecondaryChange From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 1.

The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.

Time frame:
52 weeks
Reported as:
Mean · mmHg
Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 1.
mmHgCohort 1
Week 4-10.1 ± 15.21
Week 8-13.1 ± 16.72
Week 12-21.5 ± 15.80
Week 16-25.4 ± 15.09
Week 26-26.3 ± 15.97
Week 36-27.3 ± 16.63
Week 46-28.1 ± 17.21
Week 56-25.2 ± 18.05
Final Visit-22.1 ± 18.64
SecondaryChange From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 2

The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.

Time frame:
52 weeks
Reported as:
Mean · mmHg
Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 2
mmHgCohort 2
Week 4-14.4 ± 13.57
Week 8-17.5 ± 15.07
Week 12-23.8 ± 15.97
Week 16-26.2 ± 15.65
Week 26-24.8 ± 15.25
Week 36-22.5 ± 14.89
Week 46-23.8 ± 15.35
Week 56-24.2 ± 15.96
Final Visit-22.7 ± 17.14
SecondaryChange From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 1.

The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.

Time frame:
52 weeks.
Reported as:
Mean · mmHg
Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 1.
mmHgCohort 1
Week 4-8.9 ± 8.73
Week 8-11.0 ± 9.97
Week 12-15.9 ± 9.12
Week 16-18.7 ± 9.06
Week 26-18.6 ± 9.15
Week 36-19.9 ± 9.13
Week 46-19.8 ± 9.67
Week 56-18.4 ± 9.52
Final Visit-16.5 ± 10.23
SecondaryChange From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 2.

The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.

Time frame:
52 weeks.
Reported as:
Mean · mmHg
Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 2.
mmHgCohort 2
Week 4-10.6 ± 9.23
Week 8-12.3 ± 9.05
Week 12-16.8 ± 9.48
Week 16-18.2 ± 10.28
Week 26-17.7 ± 10.95
Week 36-16.2 ± 9.08
Week 46-17.2 ± 9.57
Week 56-17.9 ± 10.85
Final Visit-16.2 ± 11.05

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) defined as any AEs, regardless of relationship to study drug, that occur after the first dose of study drug and within 14 days after last dose, or if an SAE, within 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1—30/362 (8.3%)134/362 (37%)
Cohort 2—22/307 (7.2%)106/307 (34.5%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventCohort 1Cohort 2
Chest painGeneral disorders1/3622/307
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/3622/307
Coronary artery diseaseCardiac disorders2/3620/307
Syncope vasovagalNervous system disorders2/3620/307
AnaemiaBlood and lymphatic system disorders0/3621/307
Angina pectorisCardiac disorders0/3621/307
Atrial flutterCardiac disorders0/3621/307
Atrioventricular blockCardiac disorders0/3621/307
Myocardial infarctionCardiac disorders0/3621/307
TachycardiaCardiac disorders0/3621/307
Most frequent other events
Most frequent other events
EventCohort 1Cohort 2
DizzinessNervous system disorders52/36244/307
HeadacheNervous system disorders38/36228/307
FatigueGeneral disorders32/36216/307
Urinary tract infectionInfections and infestations26/36211/307
Upper respiratory tract infectionInfections and infestations25/36220/307

Baseline characteristics

Age, Customized
Age, Customized(participants)Azilsartan Medoxomil
<45 years (Cohort 1)81
Between 45 and 64 years (Cohort 1)233
≥65 years (Cohort 1)48
<45 years (Cohort 2)90
Between 45 and 64 years (Cohort 2)193
≥65 years (Cohort 2)24
Sex/Gender, Customized
Sex/Gender, Customized(participants)Azilsartan Medoxomil
Female (Cohort 1)173
Male (Cohort 1)189
Female (Cohort 2)144
Male (Cohort 2)163
09

Study locations

41 sites
  • Ozark, Alabama, United States
  • Tallassee, Alabama, United States
  • Long Beach, California, United States
  • Santa Rosa, California, United States
  • Spring Valley, California, United States
  • Colorado Springs, Colorado, United States
  • Trumbull, Connecticut, United States
  • Waterbury, Connecticut, United States
  • Fort Lauderdale, Florida, United States
  • Hollywood, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Pembroke Pines, Florida, United States
  • Pinellas Park, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Brooklyn Center, Minnesota, United States
  • Olive Branch, Mississippi, United States
  • Rochester, New York, United States
  • Charlotte, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Akron, Ohio, United States
  • Cincinnati, Ohio, United States
  • Mogadore, Ohio, United States
  • Springdale, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Anderson, South Carolina, United States
  • Mt. Pleasant, South Carolina, United States
  • Simpsonville, South Carolina, United States
  • Bristol, Tennessee, United States
  • Nashville, Tennessee, United States
  • Arlington, Texas, United States
  • Austin, Texas, United States
  • North Richland Hills, Texas, United States
  • Salt Lake City, Utah, United States
  • Norfolk, Virginia, United States
  • San Bernardo, Santiago, Chile
  • Tijuana, BC, Mexico
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2008
First posted
Jun 12, 2008
Start
Jun 2007
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
Apr 19, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00695955
Lead sponsor
Takeda
First posted
Jun 12, 2008
Start date
Jun 2007
Primary completion
May 2010
Completion
May 2010
Results posted
Apr 19, 2011
Last update
Apr 19, 2011

Study contacts

Executive Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion